ES2600081T3 - Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII - Google Patents

Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII Download PDF

Info

Publication number
ES2600081T3
ES2600081T3 ES12777895.9T ES12777895T ES2600081T3 ES 2600081 T3 ES2600081 T3 ES 2600081T3 ES 12777895 T ES12777895 T ES 12777895T ES 2600081 T3 ES2600081 T3 ES 2600081T3
Authority
ES
Spain
Prior art keywords
factor viii
body weight
approximately
fviii
heparin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12777895.9T
Other languages
English (en)
Spanish (es)
Inventor
Hubert. METZNER
Sabine. ZOLLNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Application granted granted Critical
Publication of ES2600081T3 publication Critical patent/ES2600081T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
ES12777895.9T 2011-10-18 2012-10-18 Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII Active ES2600081T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548606P 2011-10-18 2011-10-18
EP11185648 2011-10-18
US201161548606P 2011-10-18
EP11185648 2011-10-18
PCT/EP2012/070615 WO2013057167A1 (en) 2011-10-18 2012-10-18 Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii

Publications (1)

Publication Number Publication Date
ES2600081T3 true ES2600081T3 (es) 2017-02-07

Family

ID=48140372

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12777895.9T Active ES2600081T3 (es) 2011-10-18 2012-10-18 Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII

Country Status (10)

Country Link
US (1) US9393289B2 (cg-RX-API-DMAC7.html)
EP (1) EP2768522B1 (cg-RX-API-DMAC7.html)
JP (1) JP6072810B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140083036A (cg-RX-API-DMAC7.html)
CN (1) CN103889445A (cg-RX-API-DMAC7.html)
AU (1) AU2012318279B2 (cg-RX-API-DMAC7.html)
CA (1) CA2852397A1 (cg-RX-API-DMAC7.html)
DK (1) DK2768522T3 (cg-RX-API-DMAC7.html)
ES (1) ES2600081T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013057167A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2768521B1 (en) 2011-10-18 2016-07-13 CSL Behring GmbH Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii
BR112016026842A2 (pt) 2014-06-06 2017-12-12 Octapharma Ag preparação compreendendo fator viii e peptídeos de fator de von willebrand
CA2960282C (en) * 2014-09-12 2025-09-09 The Regents Of The University Of California Human anti-CD46 macropinosome-forming antibodies and target anti-cancer therapeutic agents
CN114106146B (zh) * 2015-02-06 2025-05-06 北卡罗来纳大学查珀尔希尔分校 优化的人类凝血因子viii基因表达盒及其用途
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
FR2673632A1 (fr) 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
JP3987114B2 (ja) 1996-04-24 2007-10-03 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 不活性化耐性第▲８▼因子
WO2000024759A1 (en) 1998-10-23 2000-05-04 The Trustees Of The University Of Pennsylvania Systemic delivery of gene products via skin
CA2450125A1 (en) 2001-06-15 2002-12-27 Andre C. Schuh Gene therapy for hemophilia a
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
ES2558102T3 (es) 2003-05-06 2016-02-02 Biogen Hemophilia Inc. Proteínas quiméricas del factor de coagulación para el tratamiento de un trastorno hemostático
WO2009062100A1 (en) * 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
EP2626080A3 (en) * 2008-02-27 2014-03-05 Novo Nordisk A/S Conjugated factor VIII molecules
KR20120061898A (ko) * 2009-08-20 2012-06-13 체에스엘 베링 게엠베하 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자
WO2011095604A1 (en) * 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins

Also Published As

Publication number Publication date
CA2852397A1 (en) 2013-04-25
AU2012318279A1 (en) 2013-05-02
EP2768522B1 (en) 2016-07-27
JP6072810B2 (ja) 2017-02-01
US9393289B2 (en) 2016-07-19
US20140315815A1 (en) 2014-10-23
EP2768522A1 (en) 2014-08-27
AU2012318279B2 (en) 2015-06-04
WO2013057167A1 (en) 2013-04-25
DK2768522T3 (en) 2016-11-14
KR20140083036A (ko) 2014-07-03
CN103889445A (zh) 2014-06-25
JP2014530246A (ja) 2014-11-17

Similar Documents

Publication Publication Date Title
US11510968B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
ES2392569T3 (es) Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
ES2600081T3 (es) Uso de glucosaminoglicanos sulfatados para mejorar la biodisponibilidad del Factor VIII
JP6029674B2 (ja) 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
HK1197648A (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197648B (en) Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
HK1197649B (en) Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor viii